Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(32 sites)
United States
Ironwood Cancer and Research Centers, Chandler, Arizona Mayo Clinic Hospital, Phoenix, Arizona HonorHealth Research Institute, Scottsdale, Arizona UC San Diego Moores Cancer Center, La Jolla, California Cedars-Sinai Cancer at Cedars-Sinai Medical Center, Los Angeles, California UCLA Hematology/Oncology- Santa Monica, Los Angeles, California University of Colorado Hospital-Anschutz Cancer Pavilion, Aurora, Colorado Yale-New Haven Hospital-Yale Cancer Center, New Haven, Connecticut Mayo Clinic Cancer Center, Jacksonville, Florida Moffitt Cancer Center, Tampa, Florida The University of Kansas Clinical Research Center, Westwood, Kansas The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland Massachusetts General Hospital, Boston, Massachusetts Dana Farber Cancer Institute, Boston, Massachusetts Mayo Clinic, Rochester, Minnesota Nebraska Cancer Specialists, Omaha, Nebraska University of Nebraska Medical Center, Omaha, Nebraska Atlantic Health System, Morristown, New Jersey Northwell Health / RJ Zuckerberg Cancer Center, Lake Success, New York Columbia University Medical Center, New York, New York Memorial Sloan Kettering Cancer Center Main Campus, New York, New York Duke University Medical Center, Durham, North Carolina University of Cincinnati Medical Center, Cincinnati, Ohio Stephenson Cancer Center, Oklahoma City, Oklahoma Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania SCRI Oncology Partners, Nashville, Tennessee Baylor College of Medicine, Houston, Texas The University of Texas MD Anderson Cancer Center, Houston, Texas NEXT Oncology Dallas, Irving, Texas Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah Virginia Cancer Specialists, Fairfax, Virginia Fred Hutchinson Cancer Center, Seattle, Washington